by Richard Daverman, PhD
April 14, 2014 -- Zhejiang Hisun Pharma signed an agreement with Catalent Pharma Solutions of the US under which Catalent will provide Hisun with biosimilar cell lines. Hisun will use the technology to produce biosimilars of well-known biologics, including two arthritis treatments, Remicade (infliximab) and Humira (adalimumab), plus a treatment for leukemia, Campath (alemtuzumab). According to Catalent, its GPEx® technology reduces development time by two-thirds. More details....
Stock Symbol: (SHA: 600267)
Help employers find you! Check out all the jobs and post your resume.
